Sumatriptan Succinate

琥珀酸舒马普坦

Report date: 2026/02/24 20:00:16
NME

Base Information

Drug NameSumatriptan Succinate
Drug Alias Name舒马坦琥珀酸盐Sumatriptan SDI舒马坦sumatriptanumsumatriptan +[25] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin (5-HT) receptor agonists
TargetsSerotonin (5-HT) receptor
Therapy Area/IndicationsPost-Traumatic HeadacheHeadache Disorders, SecondaryCluster Headache +[4] 
Global Approved IndicationsCluster HeadacheMigraine Disorders
Approved Indications in ChinaCluster HeadacheMigraine Disorders
Original Approved Country/TerritoryN/A
Original Approved Date1991/01/01
Country/TerritoryCanadaUnited StatesAustralia +[7] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline PlcHainan Simcere Pharmaceutical Co LtdGlaxosmithkline Kk
Inactive CompaniesMylan Pharmaceuticals IncPfizer IncNupathe Inc +[11] 
Active IndicationsCluster HeadacheMigraine Disorders
Inactive IndicationsPost-Traumatic HeadacheHeadache Disorders, Secondary

Other Information

ATC CodeN02CC01
Related LinksWikipediaDrugBankKEGG